Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
NCT03407079
Recruiting
Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how fat cells are metabolized. Eligibility: People ages 18-60 who: * Are black or Hispanic * Weigh more than 110 pounds * Have a body mass index of 25-40 * Do not have a condition that requires drug treatment Design: Partic... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteers, Overweight
Register for Updates
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04169737
Recruiting
This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respond to treatment (refractory). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth cancer cells by blocking BCL-2 protein needed for cell growth. Immunotherapy with mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Register for Updates
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT04645160
Recruiting
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth. Objective: To find the safest and most effective dose of tivozanib to treat CCA and learn its overall response rate. Eligibility: Adults ages 18 and older with CCA not removable with surgery and have been treated with at least one type of chemotherapy. Design: Participants will be sc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Register for Updates
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
NCT05096481
Recruiting
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/30/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +11 locations
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Register for Updates
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05559879
Recruiting
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
Register for Updates
Outcomes of Irrisept Irrigation as an Adjunctive Treatment in the Management of Diabetic Foot Ulcers
NCT06024590
Recruiting
Irrisept™ irrigation containing Chlorhexidine Gluconate (CHG) 0.05% in sterile water, is an irrigation method that may help reduce bacterial load considerably more than traditional saline irrigation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Northern Illinois Foot & Ankle Specialists, Cary, Illinois +4 locations
Conditions: Diabetic Foot Ulcer
Register for Updates
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941
Recruiting
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Research Site, Orange, California +48 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/30/2025
Locations: UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California +73 locations
Conditions: Crohn's Disease
Register for Updates
Packed Red Blood Cell Transfusion During Cardiac Arrest
NCT06462027
Recruiting
The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxyg... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/30/2025
Locations: NYU Langone Health, New York, New York
Conditions: Cardiac Arrest
Register for Updates
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS
NCT06617429
Recruiting
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
04/30/2025
Locations: Cedars Sinai, Los Angeles, California +30 locations
Conditions: Angelman Syndrome
Register for Updates
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184
Recruiting
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Moffitt Cancer Center, Tampa, Florida +19 locations
Conditions: Chronic Lymphocytic Leukemia, CLL
Register for Updates
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038
Recruiting
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: NYU Langone - NYU Grossman School of Medicine, New York, New York +1 locations
Conditions: Alagille Syndrome
Register for Updates